Sylvia Zhao

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Hong Yang, Brian Higgins, Kenneth Kolinsky et al. · Cancer Research · 2010 · 405 citations

Medicine, Oncology, Pharmacology +16

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With <i>EGFR</i>-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Li Zhang, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2018 · 331 citations · Full text

Medicine, Oncology, Pharmacology +15

Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite

Ulrike Glaenzel, Yi Jin, Regine Hansen et al. · Drug Metabolism and Disposition · 2020 · 70 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +14

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

Marc S. Raab, Sheeba K. Thomas, Enrique M. Ocio et al. · Leukemia · 2019 · 68 citations

Medicine, Oncology, Pharmacology +11

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts

Yung‐Jue Bang, Wu‐Chou Su, Martin Schüler et al. · Cancer Science · 2019 · 61 citations · Full text

Pharmacy, Oncology, Pharmacology +13